Loading...

Katy Tsai, MD

TitleHS CLINICAL INSTRUCTOR
SchoolUCSF School of Medicine
DepartmentMedicine
Address1600 Divisadero
San Francisco CA 94115
Phone415-502-5483
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Brown UniversityM.D.2010Alpert Medical School
    UNC Chapel HillResidency2013Internal Medicine
    UCSFFellowship2016Medical Oncology

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Loo K, Tsai K, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Alvarado MD, Rosenblum MD, Daud AI. Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2017 Jul 20; 2(14). PMID: 28724802.
      View in: PubMed
    2. Daud A, Tsai K. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist. 2017 May 18. PMID: 28526719.
      View in: PubMed
    3. Tumeh PC, Hellmann MD, Hamid O, Tsai K, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 Apr 14. PMID: 28411193.
      View in: PubMed
    4. Nosrati A, Tsai K, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TD, Levesque M, Dummer R, Hamid O, Daud A. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer. 2017 Mar 21. PMID: 28324889.
      View in: PubMed
    5. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong AN, Park JJ, McQuade JL, Shoushtari AN, Tsai K, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2016 Sep 29. PMID: 27687304.
      View in: PubMed
    6. Tsai K, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L, Daud AI. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016; 4:58. PMID: 27660712.
      View in: PubMed
    7. Algazi AP, Tsai K, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-1L antibodies. Cancer. 2016 Aug 17. PMID: 27533448.
      View in: PubMed
    8. Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai K, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Aug 17. PMID: 27533633.
      View in: PubMed
    9. Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum MD, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016 Aug 15. PMID: 27525433.
      View in: PubMed
    10. Tsai K, Daud AI. Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Oncol. 2015; 8(1):123. PMID: 26518223; PMCID: PMC4628394.
      View in: PubMed, PubMed Central
    11. Tsai K, Daud AI. The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs. 2015 Apr; 75(6):563-75. PMID: 25802230.
      View in: PubMed
    12. Cavanaugh JJ, Jones CD, Embree G, Tsai K, Miller T, Shilliday BB, McGuirt B, Roche R, Pignone M, DeWalt DA, Ratner S. Implementation Science Workshop: primary care-based multidisciplinary readmission prevention program. J Gen Intern Med. 2014 May; 29(5):798-804. PMID: 24687289; PMCID: PMC4000330.
      View in: PubMed, PubMed Central
    13. Tsai K, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother. 2014; 10(11):3111-6. PMID: 25625924; PMCID: PMC4514131 [Available on 01/27/16].
      View in: PubMed, PubMed Central
    14. Tsai K, Marques F, Myers DL, Sung VW. Association between obesity, sexual activity and sexual function in women with pelvic floor disorders. Female Pelvic Med Reconstr Surg. 2010 Nov; 16(6):331-5. PMID: 22453616.
      View in: PubMed
    15. Oxman DA, Chow JK, Frendl G, Hadley S, Hershkovitz S, Ireland P, McDermott LA, Tsai K, Marty FM, Kontoyiannis DP, Golan Y. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother. 2010 Jul; 65(7):1460-5. PMID: 20430790.
      View in: PubMed
    Katy's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (31) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (7) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    Back to TOP